 |
市場調査レポート
商品コード
962951
神経痛治療の世界市場：治療別、エンドユーザー別および地域別予測による市場規模の調査(2020年～2027年）Global Neuralgia Treatment Market Size study, by Treatment (Drug Based, Surgery), by End-User (Hospitals & Clinics, Ambulatory Surgery Center, Others) and Regional Forecasts 2020-2027 |
||||||
| 神経痛治療の世界市場：治療別、エンドユーザー別および地域別予測による市場規模の調査(2020年～2027年） |
|
出版日: 2020年10月01日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2-3営業日
|
世界の神経痛治療の市場規模は2019年に約18億米ドルであり、2020年から2027年の予測期間にわたって6％を超える成長率で成長すると予想されています。神経痛は、神経の損傷または炎症により、激しい痛みを引き起こすことです。神経痛の治療手順は、糖尿病、心血管疾患など、神経の損傷によって引き起こされる障害を治療するのに役立つ効果的な治療であることが証明されています。神経痛治療法には、圧を和らげるための手術、糖尿病患者の血中の糖レベルの調節、理学療法、痛みを軽減するための硬膜外注射などがあります。さらに、神経痛治療市場の拡大は、より良い診断基準オプションの存在と神経痛治療サービスへのアクセスが世界中で絶え間なく拡大しているという事実に大きく帰属しています。さらに、世界中の高齢者人口の増加に伴う糖尿病と三叉神経痛の有病率の上昇は、予測期間中の市場のCAGRに関与する要因の一つです。国際糖尿病連合（IDF）によると、2019年には世界中で20～79歳の成人が4億6,300万人、糖尿病を患っており、この数は2045年までに約7億人に達する可能性があります。これにより、神経痛治療の需要が高まり、世界中の市場成長が加速することが期待されます。ただし、熟練したヘルスケア専門家の不足や治療の高コストは、2020年から2027年の予測期間にわたって市場の成長を抑制する可能性がある要因の一つです。
当レポートでは、神経痛治療市場を調査し、市場概要、市場の成長要因および阻害要因の分析、治療別・エンドユーザー別・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイル、市場機会など、包括的な情報を提供しています。
Global Neuralgia Treatment Market is valued approximately at USD 1.8 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 6% over the forecast period 2020-2027. Neuralgia is an anomalous symptom which causes intense and mostly severe pain, due to damaged or irritated nerve. Neuralgia treatment procedures are proven to be an effective treatment option, which helps to cure disorders caused by the damages nerve, including diabetes, cardiovascular diseases, and many more. Potential neuralgia treatment methods may include surgery to ease the pressure, regulate sugar level in the blood of diabetic patient, physical therapy, epidural injections to reduce pain, etc., which ultimately expand the scope of neuralgia treatment around the world. Further, the increase in the neuralgia treatment market is significantly imputed to the fact that the presence of better diagnostic criteria options and access to neuralgia treatment service is relentlessly expanding across the globe. Moreover, the rise in prevalence of diabetes and trigeminal neuralgia along with growing geriatric population around the world are the few other factors responsible for the CAGR of the market during the forecast period. According to the International Diabetic Federation (IDF), there were 463 million adults aged between 20-79 years are living with diabetes in 2019 worldwide, and this prevalence is likely to reach at almost 700 million by the year 2045. Likewise, as per the IDF Diabetes Atlas in 2019, the numbers of diabetic patients in Europe is likely to reach around 68 million by the year 2045, and the total health expenditure for the treatment of diabetes is valued at USD 214 billion. This, in turn, is expected to strengthen the demand for neuralgia treatment, accelerating the market growth all over the world. However, the high cost of the treatment coupled with the lack of skilled healthcare professionals are the few factors restraining the market growth over the forecast period of 2020-2027.
The regional analysis of the global Neuralgia Treatment market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the growing awareness among people for neuralgia treatment along with the presence of a significant number of market vendors in the region. Whereas Asia-Pacific is anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as the rise in prevalence of diabetes and neuralgia disorder followed by the growing aging population in the countries, such as China and India, would create lucrative growth prospects for the Neuralgia Treatment market across the Asia-Pacific region.
Major market player included in this report are:
GlaxoSmithKline PLC
Pfizer Inc.
Novartis AG
Biogen Inc.
Cadila Healthcare Limited
Lundbeck Pharmaceuticals LLC
Allergan Plc
Merz Pharma GmbH & Co.
Trigemina Inc.,
Abbott Laboratories
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment:
Drug Based
Surgery
By End-User:
Hospitals & Clinics
Ambulatory Surgery Center
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2017, 2018
Base year - 2019
Forecast period - 2020 to 2027
Target Audience of the Global Neuralgia Treatment Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
比較リスト
